The important attenuation of renal fibrosis in these models is consistent with the antifibrotic actions of KCa3.1 inhibitors in mouse models of unilateral ureteral obstruction (83), diabetic kidney disease (84), and cisplatin-induced acute kidney injury (85), as well as in liver (86), lung (87, 88), and other extrarenal tissues. Here, KCNN4 is linked to diabetic kidney disease.